The Oncology Brothers recap the discussion on treatment practices for patients with bladder cancer.
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Nadofaragene Firadenovec Yields Responses in BCG-Unresponsive NMIBC
Data from a Japanese trial add to the body of evidence supporting the favorable efficacy and safety of nadofaragene firadenovec for this NMIBC population.
NIAGARA Study is the Forefront of Post-ASCO GU Discussion in Bladder Cancer
The Oncology Decoded podcast highlighted the impact of the results from the NIAGARA trial for patients with bladder cancer in a post-ASCO GU discussion.
Durvalumab Combo Shows Encouraging Preliminary Data in High-Risk UTUC
Combining durvalumab with chemotherapy produced a good safety profile without increasing surgical risk in the phase 2 iNDUCT-GETUG V08 trial.
Oncology Peer Review On-The-Go: Neoadjuvant Chemotherapy for Elderly Patients with Muscle-Invasive Bladder Cancer
Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.
Cretostimogene Grenadenorepvec Yields Sustained Antitumor Activity in NMIBC
No grade 3 or higher treatment-related adverse effects or deaths were reported among those with non-muscle invasive bladder cancer in the BOND-003 trial.
UGN-102 Yields Enduring 18-Month Responses in Low-Grade NMIBC
In patients with low-grade intermediate-risk non-muscle invasive bladder cancer who achieved a CR at 3 months with UGN-102, the 18-month DOR was 80.6%.